Cosupplementation with DHA and medium‐chain triglycerides ameliorates NAFLD and reduces amyloid‐β accumulation by modulating hepatic lipid metabolism in APP/PS1 mice - Zhang, Dalong; Wang, Zehao; Wang, Xiaojun; Yue, Wenbo; Zhang, Lu; Gao, Zheng; Li, Min; Zhou, Xiaoli; Li, Zhenshu; Huang, Guowei; Li, Wen; Zhou, Dianming; et al. (Lipids, 2025)
Keywords: Alzheimer Disease - metabolism; Amyloid beta-Peptides - metabolism; Amyloid beta-Protein Precursor - genetics; Amyloid beta-Protein Precursor - metabolism; amyloid‐β clearance; Animals; Dietary Supplements; Disease Models, Animal; docosahexaenoic acid; Docosahexaenoic Acids - administration & dosage; Docosahexaenoic Acids - pharmacology; lipid metabolism; Lipid Metabolism - drug effects; Liver - drug effects; Liver - metabolism; Male; medium‐chain triglycerides; Mice; Mice, Inbred C57BL; Mice, Transgenic; NAFLD; Non-alcoholic Fatty Liver Disease - drug therapy; Non-alcoholic Fatty Liver Disease - metabolism; Non-alcoholic Fatty Liver Disease - pathology; Triglycerides - administration & dosage; Triglycerides - pharmacology; medium‐chain triglycerides; NAFLD; amyloid‐β clearance; docosahexaenoic acid; lipid metabolism